EL-32 Muscle Preservation Therapy Advances to Manufacturing Optimization
ELAB has more than doubled off its 52-week low of $1.62.
Summary
NorthStrive Biosciences, a wholly-owned subsidiary of PMGC Holdings Inc., announced the successful transfer of its EL-32 Working Cell Bank to a U.S. facility, initiating manufacturing optimization. This critical step aims to increase production yield and establish a cost-efficient, scalable process for EL-32, a dual myostatin asset targeting muscle preservation with GLP-1 therapies. This development marks a significant advancement for PMGC's life sciences segment, which has not been featured in recent news dominated by financing activities and new defense/aerospace subsidiaries. For a micro-cap company, this manufacturing milestone de-risks the product development pathway, moving EL-32 closer to investigational new drug (IND)-enabling activities and potential future commercialization. Investors should monitor further progress in manufacturing and any upcoming announcements regarding clinical development.
At the time of this announcement, ELAB was trading at $5.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.3M. The 52-week trading range was $1.62 to $466.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.